Wednesday, November 11, 2020
Five Important Questions About Pfizer’s COVID-19 Vaccine | Kaiser Health News
Five Important Questions About Pfizer’s COVID-19 Vaccine | Kaiser Health News: The drugmaker says its mRNA vaccine worked in 90% of patients in its trial, but some observers question how long immunity will last and who will benefit.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment